Dissemin is shutting down on January 1st, 2025

Published in

Springer, Advances in Experimental Medicine and Biology, p. 409-419, 2010

DOI: 10.1007/978-1-4419-6612-4_43

Links

Tools

Export citation

Search in Google Scholar

Lessons from anti-TNF biologics: Infliximab failure in a TRAPS family with the t50M mutation in TNFRSF1A

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Tumour necrosis factor (TNF) receptor-associated syndrome (TRAPS) is a chronic inherited autoinflammatory disorder. Typical features of TRAPS include recurrent fever, myalgia, rashes, and joint and abdominal pains. At the molecular level, TRAPS is associated with autosomal dominant mutations in the gene encoding the 55 kDa TNF receptor (TNFRSF1A). TRAPS affords a unique opportunity to study the biology of TNF in humans, as it is the only human disease currently known to be caused by mutations in the TNFR1 receptor. Although the inflammatory attacks of TRAPS generally fit with the notion of TNF as an inflammatory cytokine, there remain a number of questions to be answered. In particular, why do only certain patients present with cachexia, why do some patients develop systemic amyloidosis and not others, and why is erosive arthritis not seen in TRAPS although it is observed in TNF transgenic mice [20]? Perhaps some of these outcomes are related to the specific mutations seen in TRAPS, whereas others may be the result of still-undefined environmental or genetic factors. With the identification of new TRAPS mutations, it is likely that additional pathogenetic mechanisms will be identified.